Expanded Partnership Between Just – Evotec Biologics and Sandoz Enhances Biosimilar Development and Supply Security

Expanded Partnership Between Just – Evotec Biologics and Sandoz Enhances Biosimilar Development and Supply Security

(IN BRIEF) Just – Evotec Biologics and Sandoz have expanded their strategic partnership to advance the development and commercial manufacturing of biosimilars. This enhanced collaboration includes additional biosimilars in Sandoz’s pipeline and ensures long-term supply through Just – Evotec Biologics’ new manufacturing facility in Toulouse, France. The partnership leverages Just – Evotec Biologics’ innovative design and manufacturing technologies, aiming to improve global access to medicines. Dr. Matthias Evers of Evotec highlighted the potential to benefit millions of patients and affirmed the significance of the new Toulouse facility in securing commercial supply.

(PRESS RELEASE) HAMBURG, 9-Jul-2024— /EuropaWire/ — Just – Evotec Biologics, a segment of Evotec SE, and Sandoz have announced an expansion of their strategic partnership, aiming to bolster the development and commercial manufacturing of biosimilars. This move could see additional biosimilars being added to Sandoz’s development pipeline, further securing long-term commercial supply.

Just – Evotec Biologics will receive financial compensation following early scientific validation, with additional funding contingent upon meeting specific development milestones from 2025. This agreement underscores Just – Evotec Biologics’ commitment to providing a steady commercial supply of biosimilars to Sandoz, facilitated by their newly established J.POD® biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France.

The partnership, which began in May 2023, focuses on leveraging Just – Evotec Biologics’ advanced, data-driven design and continuous manufacturing technology platform, J.DESIGN. This technology aims to deliver high-quality and cost-efficient products, aligning with Evotec’s mission to enhance global access to medicines.

Dr. Matthias Evers, Chief Business Officer of Evotec, expressed enthusiasm about the expanded partnership: “We are thrilled to expand our collaboration with Sandoz, building on our prior successes. Introducing additional molecules has the potential to improve access for millions of patients. Our commercial manufacturing in Toulouse will ensure a reliable long-term supply for Sandoz’s biosimilar portfolio, validating our strategy to establish our second J.POD® in Toulouse.”

About Sandoz
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. 20,000 people of more than 100 nationalities work together to ensure 800 million patient treatments are provided annually by Sandoz, generating substantial global healthcare savings and an even larger total social impact. Its leading portfolio of 1,500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to the year 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the first biosimilar in 2006. In 2023, Sandoz achieved sales of USD 9.6 billion.

About Just – Evotec Biologics
Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at www.just-evotecbiologics.com.

About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Media Contact:

email: info@evotec.com
Tel: +49 40 560 81 0

SOURCE: Evotec

Follow EuropaWire on Google News

Comments are closed.